Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 15193-51-8 | MDL No. : | MFCD01663357 |
Formula : | C8H7NO2S | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | STFOYVOEMLDYJL-UHFFFAOYSA-N |
M.W : | 181.21 | Pubchem ID : | 27132 |
Synonyms : |
|
Num. heavy atoms : | 12 |
Num. arom. heavy atoms : | 9 |
Fraction Csp3 : | 0.12 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 2.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 48.94 |
TPSA : | 70.33 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.18 cm/s |
Log Po/w (iLOGP) : | 1.74 |
Log Po/w (XLOGP3) : | 1.73 |
Log Po/w (WLOGP) : | 1.6 |
Log Po/w (MLOGP) : | 1.03 |
Log Po/w (SILICOS-IT) : | 3.25 |
Consensus Log Po/w : | 1.87 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.54 |
Solubility : | 0.52 mg/ml ; 0.00287 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.82 |
Solubility : | 0.272 mg/ml ; 0.0015 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -3.0 |
Solubility : | 0.18 mg/ml ; 0.000991 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 2.02 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
67% | Stage #1: With copper(l) iodide; sodiumsulfide nonahydrate In N,N-dimethyl-formamide at 80℃; Inert atmosphere Stage #2: With acetic acid In N,N-dimethyl-formamide at 130℃; for 36 h; Inert atmosphere |
General procedure: A Schlenk tube was charged with ethyl 2-iodo-phenylcarbamates (1 mmol), CuI (19mg, 0.1 mmol), and Na2S*9H2O (3 mmol). The tube was evacuated and backfilled with argon (3 times), and the 2 mL of DMF was added. The reaction mixture wasstirred at 80 °C for 10-16 h, then 3 mL of AcOH was added to the cooled reaction mixture and the mixture was stirred at 130 °C for another 36 h. Saturated NaHCO3 (10mL) was added and the mixture was extracted with ethyl acetate. The organic layer was washed with H2O, brine, and dried over Na2SO4. After removal of the solvent in vacuo, the residue was purified by column chromatography on silica gel to provide the desired benzothiazolone. |
[ 80567-66-4 ]
4-Methoxybenzo[d]thiazol-2(3H)-one
Similarity: 0.85
[ 2182-73-2 ]
6-Methoxybenzo[d]thiazole-2(3H)-thione
Similarity: 0.69
[ 383865-57-4 ]
4-Methoxy-7-morpholinobenzo[d]thiazol-2-amine
Similarity: 0.57
[ 55690-60-3 ]
5-Methoxybenzo[d]thiazole-2-thiol
Similarity: 0.56
[ 71675-86-0 ]
4-Amino-5-(ethylthio)-2-methoxybenzoic acid
Similarity: 0.56
[ 80567-66-4 ]
4-Methoxybenzo[d]thiazol-2(3H)-one
Similarity: 0.85
[ 56354-98-4 ]
6-Aminobenzo[d]thiazol-2(3H)-one
Similarity: 0.83
[ 199475-45-1 ]
5-Bromobenzo[d]thiazol-2(3H)-one
Similarity: 0.76
[ 62266-82-4 ]
6-Bromobenzo[d]thiazol-2(3H)-one
Similarity: 0.75
[ 80567-66-4 ]
4-Methoxybenzo[d]thiazol-2(3H)-one
Similarity: 0.85
[ 56354-98-4 ]
6-Aminobenzo[d]thiazol-2(3H)-one
Similarity: 0.83
[ 199475-45-1 ]
5-Bromobenzo[d]thiazol-2(3H)-one
Similarity: 0.76
[ 62266-82-4 ]
6-Bromobenzo[d]thiazol-2(3H)-one
Similarity: 0.75